Background. Pneumonia is commonly diagnosed in immunosuppressed individuals. The risk and attributable morbidity of first hospitalization for pneumonia among renal transplant candidates and recipients were compared to those of population controls.
Solid organ transplant recipients receiving immunosuppressive therapy are susceptible to both common and opportunistic infections. Among renal transplant recipients in the United States, infections rank as the second most common cause of death [1] . Pneumonia is a frequent cause of morbidity and mortality in patients receiving immunosuppressive therapy and remains a significant economic burden on healthcare systems [2] [3] [4] . Previous studies have reported increased rates of pneumonia among renal transplant recipients compared with the general population [1, 5, 6] .
In renal transplant recipients, transplant failure generally leads to the reinstitution of dialysis and, therefore, reduction or complete withdrawal of immunosuppressive treatment [7] . This context offers a unique opportunity to examine the impact of reducing or ceasing iatrogenic immunosuppression on the infection-risk profile. Among transplant recipients, the incidence of infection-related cancer is reduced following the withdrawal of iatrogenic immunosuppression [8] . However, data are lacking regarding the impact of reduced immunosuppression on the risk of infection.
The purpose of this study was to (1) compare the risk of pneumonia requiring admission in the general population to that of renal transplant candidates ( patients on the waiting list for first-time renal transplantation), renal transplant recipients during periods of transplant function (and immunosuppression), and dialysis patients after transplant failure; (2) identify risk factors for pneumonia in renal transplant recipients; and (3) estimate the risk of graft loss and mortality following hospitalization for pneumonia.
PARTICIPANTS AND METHODS

Study Design and Setting
We conducted a population-based, nationwide cohort study among renal transplant candidates and recipients in Denmark during the period 1990-2009. We defined persons with endstage renal disease (ESRD) as patients in continuous dialysis for at least 90 days, patients with severe renal insufficiency on the waiting list for renal transplantation, or patients with renal grafts. The estimated prevalence of ESRD in Denmark is 0.08% [9] .
In Denmark, the treatment of patients with ESRD is centralized to 15 departments of nephrology, 4 of which had status as transplantation centers during the study. Since 1 January 1990, these 15 departments have reported ESRDrelated treatment data to the Danish Nephrology Registry (DNR) database [9] .
In addition to treatment data, the DNR database also contains transplant wait-list data and information about recipient and donor tissue types.
Study Population
Renal transplant candidates or recipients who were at least 16 years of age and experienced no prior hospitalization for pneumonia at the time of ESRD diagnosis were included in the study. Renal transplant candidates and recipients were grouped into 3 categories according to their treatment status:
1. Renal transplant candidates were patients on the waiting list for first-time renal transplantation. Most transplant candidates received hemodialysis or peritoneal dialysis therapy prior to transplantation.
2. Renal transplant recipients were first-time renal transplant recipients with a functioning graft (on immunosuppressive therapy).
3. Renal graft loss patients were first-time renal transplant recipients experiencing renal graft loss in which immunosuppressive treatment was ceased or reduced and dialysis resumed.
Thus, patients could contribute risk time to >1 of the subgroups during the study period. However, some transplant recipients received transplants outside the waiting list if the treating physician considered that the best option for the patient was to receive a living donor transplant.
We used the Danish Civil Registration System (CRS), a national registry of all Danish residents, to obtain information on date of birth, sex, date of migration, and date of death. Through CRS, multiple registrations of the same patient were prevented. The CRS is updated within a week of a person's birth, death, or emigration [10] .
Population Controls
Individuals without ESRD were sampled from the CRS and used for comparative analyses. For each renal transplant candidate and recipient, we identified 19 controls matched for sex and age (month and year of birth) on the day the patient was diagnosed with ESRD.
Identification of Hospitalized Pneumonia
The Danish National Patient Registry (DNPR) has collected nationwide data on all somatic hospital admissions since 1977. For each hospitalization, the DNPR records the personal identification number (CRS number), hospital department involved, discharge diagnoses, and dates of admission and discharge. From 1977 to 1993, diagnosis codes were coded with reference to the International Classification of Diseases, Eighth Revision (ICD-8); since 1994, they have been coded with reference to the International Classification of Diseases, Tenth Revision (ICD-10). The physician discharging the patient registered the diagnosis codes at the time of discharge.
We used the DNPR to identify all hospital admissions with a discharge diagnosis of viral or bacterial pneumonia using ICD-8 codes 480.XX-486.XX, 073.XX, or 471.XX, and ICD-10 codes J11.0 (influenza with pneumonia), J12.x-J18.x ( pneumonia), A481.x, (ornithosis), or A709.x (legionellosis). Thus, both community-acquired and hospital-acquired pneumonias were included. The onset of pneumonia was defined as the date of hospital admission. Pneumocystis jiroveci pneumonia and fungal pneumonia were not counted as episodes of pneumonia in this study.
Validation of Discharge Diagnoses of Pneumonia
To validate the diagnosis of pneumonia identified in the DNPR, we reviewed a random sample of 75 hospital records representative of the study period (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) .
The review included patients who received renal transplants and had a discharge diagnosis of pneumonia in the DNPR. We confined the review to Aarhus County because data quality in the DNPR is considered to be uniform throughout the country [11] .
Pneumonia diagnoses for population controls without ESRD were validated previously [12] , and identical diagnostic criteria were used in our validation of diagnoses. The discharge diagnosis of pneumonia was confirmed when the patient's chest radiographic examination showed an infiltrate and at least 1 of the following clinical or laboratory findings were present: body temperature ≥37.5°C, cough, dyspnea, chest pain or crepitations coincident with the area of infiltrate, increased amount of sputum, purulent sputum, relevant microorganism isolated from the blood culture, leukocyte count ≥12 × 10 9 cells/L, or C-reactive protein concentration >100 mg/dL. We determined the percentage of episodes recorded in the DNPR that fulfilled our criteria for confirmed pneumonia.
Comorbidity Data
We calculated Charlson comorbidity index (CCI) score for each study participant based on the complete hospital discharge history. The CCI includes 19 major disease categories and has been adapted and validated for use with hospital discharge data in ICD databases. The CCI is considered a reliable method for measuring comorbidity in clinical research [13] . In this study, the CCI score did not include renal disease.
Statistical Analyses
Time at Risk Subjects were observed from 1 January 1990, the date of their first appearance on the transplant waiting list, or the date of their renal transplantation (if the patient received a transplant without being on the waiting list), whichever came last. Population controls entered the study on the same day as their matched renal patient. We determined time from the date of first observation until the date of first hospitalization for pneumonia, retransplant, death, or emigration, or 31 December 2009, whichever came first.
Incidence Rate and Incidence Rate Ratio
The incidence rate (IR) of first-time hospitalization for pneumonia was calculated for renal transplant candidates, renal transplant recipients, and renal graft loss patients and compared to the IR for background controls. We determined separate incidence rate ratios (IRRs) for pneumonia for the 3 study groups.
The causative organism according to the discharge diagnosis were tabulated for ESRD patients and population controls.
Impact of Comorbidity on Risk of Pneumonia
Comorbidity as assessed by the CCI score was calculated for each individual on the date of their study entry. Three comorbidity levels were defined according to the CCI score: 0, low; 1-2, medium; ≥3, high.
Poisson Regression Analysis
Risk factors for first-time hospitalization for pneumonia in renal transplant recipients were assessed by Poisson regression.
Variables
The following variables were entered into the model: recipient sex, donor type (cadaveric donor, living unrelated donor, and living related donor), cause of ESRD (glomerulonephritis, diabetes mellitus types I and II, chronic interstitial nephritis, hypertensive kidney disease, polycystic kidney disease, nephrosclerosis, and vasculitis), prior dialysis time (no dialysis, <1, 1-3, and >3 years), human leukocyte antigen (HLA) mismatches (HLA AB mismatches <3/≥3 and HLA DR mismatches <2/2), donor age (<50, 50-59, and ≥60 years), and the following time-varying covariates: recipient age (<50, 50-59, and ≥60 years), calendar period (1990-1994, 1995-1999, 2000-2004, and 2005-2009) , and posttransplant time (<1, 1, 2, and ≥3 years).
Pneumonia and Risk of Graft Loss
We investigated whether hospitalization for pneumonia was associated with risk of graft loss in renal transplant recipients. IRs and IRRs (adjusted for CCI score and age) were calculated using Poisson regression with pneumonia as the exposure and graft loss as the outcome.
Mortality Following Hospitalization for Pneumonia
We computed Kaplan-Meier plots for the 30-and 90-day mortality of individuals in the 3 risk groups and their matched population controls. Furthermore, we computed crude and adjusted 30-and 90-day mortality rate ratios (MRRs) using Cox regression. We included sex, age, and CCI score on admission in the adjusted MRR. We used Stata software, version 11.0 (StataCorp, College Station, Texas) for statistical analyses. The study was approved by the Danish Data Protection Agency.
RESULTS
Study Population
The study population consisted of 4729 renal transplant candidates and recipients and 81 757 population controls, providing 25 546 and 704 329 person-years of observation, respectively. In total, 2411 of the patients were transplant candidates, 3092 renal transplant recipients, and 876 graft loss patients. A first-time hospitalization for pneumonia was identified in 958 ESRD patients and in 2932 population controls.
Incidence of Pneumonia
The IR of first-time hospitalization for pneumonia was lowest, 31.2 hospitalizations per 1000 person-years (95% CI, 28.8-33.9), among renal transplant recipients and highest, 64.8 hospitalizations per 1000 person-years (95% CI, 55.7-75.4) among patients with graft loss ( Table 1 ).
Impact of Comorbidity on Pneumonia Risk
The risk of first-time hospitalization for pneumonia was considerably higher in patients with a medium or high comorbidity score than in those with no registered comorbidity (Table 2) . Comparing renal transplant recipients without comorbidity (other than ESRD) and population controls without comorbidity yielded an IRR of 8.03 (95% CI, 6.84-9.40). Similarly, the IRR for renal transplant candidates and graft loss patients with no comorbidity and their population controls was 8.52 (95% CI, 6.19-11.5) and 13.7 (95% CI, 9.10-19.9), respectively. 
Risk Factors for Hospitalization for Pneumonia Among Renal Transplant Recipients
Pneumonia and Risk of Graft Loss
Exploring potential associations between pneumonia and graft loss among renal transplant recipients (n = 962) revealed an IR for graft loss following pneumonia of 76.0 per 1000 person-years (95% CI, 65.8-87.9) compared with 43.4 per 1000 person-years (95% CI, 40.5-46.6) for patients without prior pneumonia. When adjusting for CCI score and age, renal transplant recipients with pneumonia had 78% greater risk of graft loss than recipients without pneumonia (adjusted IRR = 1.78; 95% CI, 1.52-2.10).
Mortality Following Hospitalization for Pneumonia
In ESRD patients, the 30-day cumulative mortality was 10% (95% CI, 7%-15%) among renal transplant candidates, 7% (95% CI, 5%-9%) among renal transplant recipients, and 7% (95% CI, 4%-12%) among graft loss patients (Table 4) .
Compared to population controls, the 30-day adjusted MRRs were 0.70 (95% CI, .42-1.16) for renal transplant candidates, 0.63 (95% CI, .44-.91) for renal transplant recipients, and 0.94 (95% CI, .48-1.84) for graft loss patients. Correspondingly, the adjusted 90-day MRRs were 0.66 (95% CI, .43-1.02) for renal transplant candidates, 0.55 (95% CI, .40-.75) for renal transplant recipients, and 0.73 (95% CI, .43-1.22) for graft loss patients.
Validation of Discharge Diagnoses of Pneumonia
We reviewed a random sample of 75 medical records with a discharge diagnosis of pneumonia. Sixty-five of the episodes fulfilled criteria for confirmed pneumonia, equivalent to a positive predictive value of 87% (95% CI, 76%-93%).
DISCUSSION
Our study is among the first to investigate the impact of immunocompetence before, during, and after successful engraftment of a renal transplant on the risk of infection. We found that the risk of first-time hospitalization for pneumonia was 10-fold higher among renal transplant candidates, 8-fold higher among renal transplant recipients, and 13-fold higher among patients with graft loss compared to matched population controls. Even after adjusting for age and comorbidity, the risk of pneumonia remained high during the entire study period. We also identified a range of potential modifiable risk factors for pneumonia among renal transplant recipients, and showed that hospitalization for pneumonia is strongly associated with increased risk of renal graft loss and mortality. Collectively, these findings suggest that profound immunodeficiency persists before, during, and after successful renal engraftment leading to excess morbidity and mortality from common infections, such as pneumonia.
In the present study, graft loss patients carried the highest risk of pneumonia, followed by renal transplant candidates and renal transplant recipients. A study by Sarnak et al [14] found that the incidence rate of pulmonary infectious mortality in renal transplant recipients is approximately 2-fold higher than in the general population but lower than in hemodialysis and peritoneal dialysis patients. Several reasons may explain why dialysis patients are more susceptible to pulmonary infections: alterations in respiratory drive, mechanics, muscle function, and gas exchange are frequent if not invariable consequences of uremia [15] . Furthermore, fluid overload during dialysis, particularly in the lungs, an accumulation of dialysis fluid in the abdomen affecting the respiration, and exit-site infections (eg, staphylococcal infections) could explain the excess risk of pneumonia in dialysis patients. Immunosuppressive drugs could contribute to higher rates of infection in renal transplant recipients. However, lower infection rates observed in renal transplant recipients compared with the dialysis population may be due to successful transplantation leading to a nonuremic state [14] , as well as elimination of overhydration. Previous studies indicated a rapidly reversible effect of immunosuppression on infection-related cancer risk after transplant failure [8] . Surprisingly, we found that the risk of first-time hospitalization for pneumonia remained almost 14-fold higher in patients with graft loss compared to control individuals. This finding may be explained by reappearance of a uremic state and reinstitution of dialysis [14] . In addition, intensified immunosuppression to preserve graft function may also contribute to the excess risk. Infectious diseases may cause graft rejection. Previous studies have shown an association between infection and allograft dysfunction [2, [16] [17] [18] [19] , and our findings correlate well with this. Pneumonia may be an indicator of imminent graft loss and not necessarily the cause of it, but in any case pneumonia may warrant focus on the graft. Immunosuppression is occasionally reduced during severe infections, and an infection per se may expose graft antigens. Thus, effective preventive strategies, such as influenza and pneumococcal immunization, to decrease the incidence of posttransplant infection have the potential of improving the long-term outcomes of renal allografts [16] .
The strengths of our study include the use of population-based, nationwide cohorts with inclusion of all adult first-time renal transplant candidates or recipients, minimal loss to follow-up, and the availability of comprehensive hospitalization data and data on specific transplant parameters. The CCI enabled us to adjust for underlying diseases, and the large study size provided statistical precision for the estimates. Because we considered only the first hospitalization for pneumonia, our estimates were not biased by multiple pneumonia episodes occurring in highly susceptible individuals.
Our study also had some limitations. Coding errors may occur in routine hospital discharge data, leading to misclassification in the diagnosis of pneumonia in both renal patients and the general population. Misclassification may bias the incidence of pneumonia; however, according to our diagnosis validation, the degree of misclassification was low and comparable in the 2 populations (the positive predictive value of a pneumonia discharge diagnosis among renal patients was 87% in our study and 90% in the general population [12] ). In addition, physicians may have a lower threshold for hospital admission of renal transplant recipients with signs and symptoms of pneumonia than for patients who did not undergo transplantation, which could cause us to overestimate the relative risk of pneumonia in ESRD patients. In fact, we found a nonsignificant lower short-term mortality among ESRD patients compared to population controls. This may indicate that, for some renal patients, the severity of pneumonia upon hospital admission is less than in the general population. However, this difference alone could not explain the large excess risk of pneumonia in all categories of ESRD patients.
Unfortunately, we had no information on immunosuppressive regimen and could not assess the effect of individual drugs on pneumonia. However, according to other studies [1] , risk of infection is not significantly different for specific immunosuppressive drugs. Furthermore, data on smoking status (a well-known risk factor for pneumonia) and immunization/ vaccination status were not available. Kausz et al [20] estimated vaccine utilization in the United States among patients on dialysis with predialysis chronic kidney disease and found low rates of influenza (65% and 46%, respectively) and pneumococcal vaccination (26% and 15%, respectively), vaccination rates which would have little effect on our results.
In conclusion, the risk of hospitalization for pneumonia remains high in renal transplant recipients, but it is even higher among renal transplant candidates and graft loss patients. Future challenges will be to minimize the risk of infection related to uremia and dialysis and to employ more selective and less toxic immunosuppressive therapy to prevent allograft rejection while avoiding global nonspecific immunosuppression. Future studies should also explore preventive measures, such as pneumococcal and influenza immunization, in this vulnerable population. 
